Bli medlem
Bli medlem

Du är här


XSpray Pharma AB: Redeye: Xspray Pharma - On the right track

Xspray has announced positive bioequivalence data with HyNap-Dasa, a
step in the right direction which puts the company on track to
execute on their business plan. We see the news as positive and
indicative of news to come. With this report, we raise our Base Case
to SEK 135 (120) per share. Our Bull and Bear Case remains at SEK 220
and 25 per share, respectively.

Read more and download the research report by Mathias Spinnars:

Start following Xspray Pharma at Redeye to instantly receive our
latest analyst updates and comments.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.